GE HealthCare Technologies Inc. (GEHC) recently announced the 510(k) submission to the FDA for CleaRecon DL, a deep-learning technology. The company is looking to get FDA clearance for the technology designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite.GE HealthCare is committed to assisting physicians in utilizing image guidance technologies to their maximum capacity by removing obstacles ...

GE HealthCare Technologies Inc. (GEHC) recently unveiled Sonic DL for 3D to further boost the company’s imaging portfolio. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL.By extending Sonic DL to 3D volumetric imaging, GE HealthCare is likely to expand its use beyond cardiac assessments to include brain, spine, orthopedic, and body exams. The goal of this expansion is to significantly cut scan times while maintaining the same remarkable 12 times scan ...

GE HealthCare Technologies Inc. (GEHC) recently unveiled the new Pristina Via mammography system. This system will provide mammography technologists with a suite of advanced tools that balance the demands of diagnostic accuracy and workflows to facilitate more patient-centered breast care.As GEHC continues to evolve its Senographe Pristina platform, Pristina Via brings advanced new features to help minimize repetitive tasks and streamline workflows so that mammography technologists can maintain their focus ...

GE HealthCare Technologies Inc. (GEHC) recently announced additional clinical applications of the OEC 3D mobile CBCT C-arm portfolio, which enable precise and efficient imaging during endoscopic bronchoscopy procedures in interventional pulmonology.For routine procedures like neuro-spine and orthopedic trauma, as well as interventional procedures like bronchoscopy, GE HealthCare's OEC 3D intraoperative mobile CBCT continues to show imaging superiority and versatility.Likely Trend of GEHC Stock Following the ...

DURHAM, NC and LONDON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s specialized MRI Chest Coil to now include GE HealthCare 3 Tesla (3T) MRI scanners for the visualization of Xenon-129 nuclei. With this new introduction, the Compa ...

GE HealthCare Technologies (GEHC) recently announced the receipt of FDA clearance for its SIGNA MAGNUS, a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner.This new innovative system has the potential to help detect neurological, oncological and psychiatric conditions by providing new clinical imaging and neuroscience capabilities. With SIGNA MAGNUS, GEHC is likely to provide neuroradiologists and neuroscience researchers with a tool that supports advanced imaging and biomarker resea ...

Core Insights - Albert Anthony is a Croatian-American media personality and financial contributor, reaching over 1 million investors globally since 2023 [1] - His content on Seeking Alpha averages over 25,000 views monthly, focusing on stock analysis and dividend income portfolio building [1] - In addition to financial analysis, he has engaged in city council politics in Croatia and ran for Parliament in 2024 [1] Company and Industry Summary - Albert Anthony provides curated analysis of stocks trading on major US exchanges, emphasizing a forward-looking perspective on stock performance [1] - He has experience in financial services, having worked at Charles Schwab and completed certifications from various prestigious institutions [1] - His involvement in the Croatian Economic Association indicates a commitment to economic discourse and policy development [1]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . I love it when large conglomerates spin off major business segments. This is something I have discussed in a number of articles in the past. The main reason for this is the fact that we can diversify our own portfolios. Many decades Analyst's Disclosure: I/we have a beneficial ...

Financial Data and Key Metrics - The company reported Q3 2024 revenues of $4.9 billion, with 1% organic revenue growth, in line with expectations [11] - Adjusted EBIT margin was 16.3%, up 90 basis points year-over-year, and adjusted EPS was $1.14, up 15% year-over-year [13] - Free cash flow was $651 million, up $81 million year-over-year [13] - The company raised the low-end of its full-year adjusted EBIT margin guidance to 15.8%-16% and adjusted EPS guidance to $4.25-$4.35 per share [27] Business Line Performance - Imaging segment organic revenue was down 1% year-over-year due to headwinds in China, partially offset by strength in the U.S. [18] - Advanced Visualization Solutions segment organic revenue was flat year-over-year, with increased U.S. sales offset by a decrease in China [19] - Patient Care Solutions segment organic revenue was up 2% year-over-year, driven by backlog execution [20] - Pharmaceutical Diagnostics segment delivered 7% year-over-year organic growth, driven by healthy procedure volumes [21] Market Performance - Excluding China, global sales growth was approximately 5%, and orders growth was 4% [11] - The U.S. market showed strong performance across all segments, with multiyear enterprise deals driving orders and sales [7] - China market recovery has been slow, with sales down 17% year-to-date, impacting total company sales growth by approximately 400 basis points [11][42] Company Strategy and Industry Competition - The company is focusing on innovation, particularly in Theranostics, with advancements in molecular imaging and FDA clearance for a new software tool to standardize radiation dosage measurement [10] - Investments in AI and cloud-based solutions are being made to address customer data overload and operational inefficiencies [30] - The company is optimizing its cost structure through lean initiatives and IT transformation, with expected annual savings of $4 million from software license alignment [16] Management Commentary on Operating Environment and Future Outlook - Management views the China market challenges as temporary and remains optimistic about the mid to long-term attractiveness of the market [8][41] - The company is confident in its fundamentals, supported by innovation, a strong backlog, and operational focus [32] - The company expects limited market benefit from China's stimulus through the first half of 2025 [25] Other Important Information - The company has exited the majority of Transition Service Agreements (TSAs) and is on track to exit the remaining agreements on time, positioning it well for further cost optimization [16] - The company announced Flyrcado, an FDA-approved F-18 PET myocardial perfusion imaging tracer, expected to become commercially available in the U.S. in early 2025 [28] Q&A Session Summary Question: Margins and future operating margin expansion [34] - The company has delivered strong margin performance year-to-date, with EBIT margin up 70 basis points and gross margin up 130 basis points [35] - Future margin improvements will be driven by continued focus on price, productivity initiatives, and the benefits of R&D investments [37] Question: China market trajectory and impact on sales growth [38] - The China market recovery is slow, with limited improvement expected through the first half of 2025 [39][41] - The company expects China sales to be down high teens for the full year 2024 [42] Question: Pricing and growth assumptions for 2025 [50] - The company expects pricing to follow new product introductions, with positive sales price trends in the quarter [51] - R&D investments are expected to normalize to more sustainable growth rates in 2025 [71] Question: Flyrcado pricing and market potential [46] - Flyrcado is expected to command a premium due to its improved specificity, sensitivity, and operational capabilities [47] - The company estimates potential annual revenues of over $500 million from Flyrcado once the health system infrastructure is in place [29] Question: Infrastructure requirements for Flyrcado [55] - Flyrcado requires PET systems, which may need to be acquired and installed in cardiology areas, with shared use systems expected in some institutions [57] Question: Vizamyl performance and CMS reimbursement impact [55] - Vizamyl sales in the U.S. nearly doubled quarter-over-quarter, with potential for further growth due to CMS reimbursement changes [59] Question: Pharmaceutical Diagnostics business components and growth levers [64] - The Pharmaceutical Diagnostics business includes proprietary molecules, equipment, and digital integration, with growth driven by new agents, reimbursement changes, and integrated solutions [66][68] Question: 2025 P&L building blocks and one-time items [69] - R&D growth is expected to normalize, and SG&A is expected to move with sales, with no dramatic one-time step-up in incentive compensation expected [71] Question: China's impact on 2025 growth and margin progression [73] - The company is cautious about China's recovery timing and will provide more detailed guidance in February [74] - Mid-single-digit organic revenue growth and margin expansion are expected in the medium term [74][77] Question: Q4 organic growth and confidence in sequential ramp [78] - Q4 organic growth is expected to be slightly above 2%, driven by strength in PDx, service business, and the U.S. market [79] - The company has good visibility into backlog conversion and expects similar conversion rates to historical levels [81] Question: Flyrcado market penetration and system-side impact [83] - Flyrcado's market penetration will depend on the availability of PET systems, with potential for significant conversion over a three to five-year horizon [84] - Flyrcado is expected to drive PET system sales and strengthen the company's position in the molecular imaging market [85] Question: China market steps and Flyrcado launch preparation [89] - The China market is in the first step of recovery, with funds not yet released and tenders not opened [90] - Flyrcado launch preparations include working with CMS for reimbursement and commercialization ramp-up, with expected commercialization in late Q1 2025 [90]

For the quarter ended September 2024, GE HealthCare Technologies (GEHC) reported revenue of $4.86 billion, up 0.9% over the same period last year. EPS came in at $1.14, compared to $0.99 in the year-ago quarter.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $4.86 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +7.55%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations t ...